• Home
    • Leucémie myéloïde chronique
    • Leucemia Mieloide Crónica
  • CML Experts
    • How to get the CMLer's password?
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • CML experts in America >
      • CML experts in Canada >
        • How to get the CMLer's password?
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connie Eaves
        • Dr. Josée Hébert
        • Dr. Vincent Éthier
        • Dr. Marc Lalancette
        • Dr. Luigina Mollica
        • Dr. Dennis Kim
        • Dr. Pierre Laneuville
        • Dr. Pierre Laneuville (v. fr.)
        • Dr. Conrad Vincent Fernandez
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Mark Hnatiuk
      • CML experts in US >
        • How to get the CMLer's password?
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • Rey Garcia, RN, BSN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Dr. Charles Schiffer
        • Dr. B. Douglas Smith
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Javier Pinilla-Ibarz
        • Dr. Catriona Jamieson
        • Dr. Arul Chinnaiyan
        • Dr. Ami Patel
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Franziska Michor
        • Dr. Frank Giles
        • Dr. Gabriella Hobbs
        • Dr. Ehab Atallah
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Matt Kalaycio
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Ellen K. Ritchie
        • Dr. Karen Seiter
        • Dr. Kendra Sweet
        • Dr. Michael Savona
        • Dr. Neil Shah
        • Dr. Richard T Silver
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Ronald L. Paquette
        • Dr. Sangmin Lee
        • Dr. Srinivas K. Tantravahi
        • Dr. Bin Zhang
      • CML experts in South America >
        • Dr. Michele Bianchini
        • Dra Beatriz Moiraghi
        • Dra. Carla Boquimpani
        • Dr Carolina Pavlovsky
    • CML Experts in Europe >
      • CML Expert in Belgium >
        • Pr Gregor Verhoef
      • CML expert in France >
        • Comment obtenir le mot de passe?
        • Dr. François-Xavier Mahon
        • Dr Aude Charbonnier
        • Dr. Agnès Guerci Bresler
        • Dr Pascale Cony-Makhoul
        • Dr. Delphine Rea
        • Dr. Gabriel Etienne
        • Dr. Lawrence Legros
        • Dr. Marie-Joëlle Mozziconacci
        • Dre Célia SALANOUBAT
        • Pr. Mauricette Michallet
        • Dr. François Guilhot
        • Dr. ​Emilie Cayssial
        • Dr Françoise Huguet
        • Dr. Stéphane Prost
        • Dr. Philippe Rousselot
        • Dr. Eliane Gluckman
        • Dr. Franck-Emmanuel Nicolini
      • CML expert in Italy >
        • Dr. Carlo Gambacorti-Passerini
        • Dr. Chiara Elena
        • Dr. Gianantonio Rosti
        • Dr. Massimo Breccia
        • Dr. Michele Baccarani
        • Dr. Giuseppe Saglio
      • CML expert in UK >
        • Dr. Jane Apperley
        • Dr. Richard Clark
        • Dr. Stephen O'Brien
        • Dr. Georgios Nteliopoulos
        • Dr. Adam Mead
        • Dr. Tessa L Holyoake
      • CML expert in Germany >
        • Dr. Andreas Hochhaus
        • Professor Jörg Hasford
        • Professor Oliver Hantschel​
        • Dr Susanne Saussele
        • Dr. Martin Müller
      • CML expert in Portugal >
        • Dr. Antônio Medina de Almeida
      • CML expert in Spain >
        • Dr. Juan Luis Steegmann
      • CML expert in Netherlands >
        • Dr. Jeroen J.W.M. Janssen
      • CML expert in Sweden >
        • Dr. Johan Richter
      • CML expert in Czech Republic >
        • Dr. Hana Klamova
    • CML experts in Asia >
      • Dr. Annuar Rapaee
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Uday Yanamandra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • CML experts in Africa >
      • Dr. Asmaa Quessar
      • Dr. Anthony Oyekunle
    • CML experts in Australia >
      • Dr. Ilaria Pagani
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. David T. Yeung
      • Dr. Liu Lu
      • Dr. Naranie Shanmuganathan
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • How to get the CMLer's password?
    • Introduction to CML >
      • Precision medicine in chronic myeloid leukemia
      • Philadelphia chromosome
      • BCR-ABL Transcripts
      • Sokal, Hasford, and EUTOS scores
    • General concepts >
      • Blood
      • Bone Marrow
      • DNA
      • Electrolytes
      • Stem Cells
      • Immune System >
        • Natural killer cell - NK
        • T Cells
      • Blood-Brain Barrier
    • Clinical Trials
    • Treatment response in CML
    • Resistance to treatment in CML >
      • Molecular monitoring in CML >
        • Polymerase Chain Reaction (PCR)
        • Dr. Kary Bank Mullis
      • Non-adherence of CML patients
      • Sensitive detection of BCR-ABL1 mutations
      • JAK2 Gene
    • Donor lymphocyte infusion (DLI)
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • How to get the CMLer's password?
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Imatinib
    • Tasigna (Nilotinib) >
      • Generic nilotinib
    • Sprycel (Dasatinib) >
      • Generic Dasatinib
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • Scemblix (Asciminib)
    • Tern-701
    • KF1601
    • Synribo (Omacetaxine )
    • HQP1351 (Olverembatinib)
    • Jakafi (Ruxolitinib)
    • K0706 (Vodobatinib)
    • Flumatinib
    • (Bafetinib)
    • Danusertib
    • DCC-2036 (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • ELVN-001
    • BP1001
    • S116836
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • How to get the CMLer's password?
      • Acid Uric - Gout
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Night Sweats
      • Peripheral Neuropathy in CML
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Food and Drug Interactions
    • CML and comorbidities >
      • Living with CML and diabetes
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Hypnotherapy
      • Music therapy >
        • YouTube creation by CMLer's family
        • Relaxing Music for Stress Relief. Calm Music for Meditation, Sleep, Healing Therapy, Spa
        • Debussy – Relaxing music - Clair de lune et autres...
        • Delicate music for the soul and LIFE, and birdsong soothes the nervous system.
        • Adagio for Strings (Samuel Barber)
        • Amélie Soundtrack ♥ Comptine d'Un Autre Été
        • The song "Disenchanted'
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • How to get the CMLer's password?
    • 30 years and plus survivors >
      • How to get the CMLer's password?
      • Mark Popadick
      • Mary Sullivan
      • Dr. Robert Patenaude -E
      • Skip Duffe
      • Sister Shirley Vaughn
      • Tamera Simonson
    • 20 years and plus survivors >
      • How to get the CMLer's password?
      • Doug Jenson
      • Giora Sharf
      • Joannie Clements
      • Mel Mann
      • Kevin Williams
      • Rich Jones
      • Tanja Fajon
      • Virginia Garner
    • 10 years and plus survivors >
      • How to get the CMLer's password?
      • Dan Sloan
      • Drew Johnston
      • Erin Zammett Ruddy
      • Erin Havel (Author)
      • Gary Gonzales
      • Jan Geissler
      • Jean McGlynn
      • Jo'story
      • ELLE Halliwell (Pregnancy)
      • Kayla Naton (Pregnancy)
      • Leanne
      • Mary Jane Bertram
      • Pat Elliott
      • Rob Shick
      • Tegan Kubler
      • Tom Cleaver
      • Sohag
    • New CMLers >
      • How to get the CMLer's password?
      • Skye Davidson
      • Amanda Steffy
      • Abbi Evans
      • Alyssa
      • Austin Granatowicz
      • Brown Dudley
      • Nigel
      • Katie
      • Kris
      • Ron Robbecke
    • Celebrities with CML >
      • How to get the CMLer's password?
      • Alexa Score
      • Brian Boyle
      • Carlos Carrasco
      • Charlie Schlatter
      • Doris Muramatsu
      • Dr. Richard Rockefeller
      • Greg Lemond
      • Kareem Abdul-Jabar
      • Kelvin Alston
      • Jason Blake
      • Laura Boyd
      • Lee Zeldin
      • Rick Upchurch
      • Roman Reigns
      • Ryan O'Neal
      • Tim Holcomb
    • Suzan Mc Namara and the petition
    • Bud Romine - the first patient
    • Other testimonials
    • Blogs >
      • How to get the CMLer's password?
      • Living with CML
      • Michelle D's Blog
      • Jon's Blog
      • Blogs not recently updated >
        • Access CML Drugs
        • CMKID's blog – Dislodging the bullet - 2012
        • CML Recovery - Stopping KTI -2011
        • Hans's Blog -2012
        • Elizabeth's Blog - my leukemia - 2013journey
        • Elizabeth's Blog - Heart of the rose -2011
        • Joe's Blog - 2012
        • Josh's Blog - 2014
        • Mannan's Blog -2014
        • Ian's Blog -2014
        • Matt's Blog - 2012
        • Matthew's Blog - 2014
        • Michelle's Blog -2012
        • Nayree's Blog -2011
        • Rob's Blog - 2011
  • Global News on CML
    • English - Latest CML News >
      • News -Archives 2023-2022
      • News -Archives 2021-2020
      • News -Archives 2019-2018
      • News - Archives 2017-2016
      • News Archives - 2015-2014
      • News-Archives -2013-2012
      • News - Archives 2011-2001
    • French (Français) - Dernières nouvelles
    • Spanish (Español)-Ultimas noticias
  • Links to other sites, forums and Facebook
    • Sites (English and other languages)
    • Forums (English and other languages)
    • CML on Facebook
    • CML on Twitter
    • Audio Podcast
  • Various topics
    • How to get the CMLer's password?
    • CML patients and the coronavirus
    • You’ve just been diagnosed
    • History of CML
    • CML causes
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • Increased Risk of Secondary Cancers with CML
    • Vaccination of CMLers
    • CML Blast Crisis treatment
    • Bone marrow transplant
    • Stem cells from umbilical cord blood
    • ThINKK (Therapeutic inducers of Natural Killer cell killing)
    • Children with CML
    • CML and pregnancy
    • Mutation T315I
    • Elderly patients with CML
    • Sports with CML
    • CML Awareness Day >
      • Journée mondiale de sensibilisation à la leucémie myéloïde chronique
    • The movie "Dying to Survive"
    • The movie 'The Blue Butterfly"
  • Cure possible for CML?
    • How to get the CMLer's password?
    • Hematopoietic stem cell transplantation using single UM171-expanded cord blood >
      • Greffe de cellules souches de cordon ombilical amplifiées par la molécule UM171
    • Combination of tyrosine kinase inhibitor with other medication >
      • Combinaison of hydroxychloroquine with tyrosine kinase inhibitor
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of insulin sensitizer MSDC-0600K with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
    • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
    • Inhibition of the protein Ezh2 can cure CML?
    • Inhibition of STAT5 in conjunction with standard TKI therapy
    • PROTAC-mediated Targeted Protein Degradation
    • CML vaccine
    • Can immunotherapy cure leukemia?
    • Could fasting cure chronic myeloid leukemia
    • Chimeric Antigen Receptor T-Cell Therapy
    • Can genetic sequencing help to cure leukemia?
    • Can the new drug CX-5461 cure leukemia?
    • CRISPR-Cas9 gene-editing technique
    • Presence of bcr abl fusion transcripts in healthy individua
    • Math could help cure leukemia
    • Natural Medicine >
      • Possible cure for CML in Fish Oil
      • Betel leaf may help fight CML
      • Feverfew extract (parthenolide)
      • Can dandelions kill cancer?
      • Can curcumin cure leukemia?
  • Treatment-Free remission(TFR)
    • The French trial called STIM (Stop Imatinib)
    • De-escalation of treatment
    • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
  • Educational videos (all languages)
    • Educational videos in English
    • Vidéos pédagogiques en français sur la LMC
    • Videos instructivos en español
  • Educational events
  • CML Tool Box (all languages)
    • English tool box >
      • Survey for CMLer who take asciminib
      • Survey for patients who passed TFR (Treatment-Free Remission)
    • French tool box >
      • Sondage pour les patients qui prennent l'asciminib
      • Sondage uniquement auprès des patients ayant réussi le RST( Rémission sans traitement)
    • Spanish tool box >
      • Encuesta_de_medicación_ LMC.html
    • Know your CML
    • My CML
  • CML Glossaries
  • Moral Support
    • Where to get help and support
    • Family support
    • Dances at the Cancer Research Centre
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • Stronger
    • The march toward healing
    • Be happy
  • Professionnel help and literature
    • Dr. Siddhartha Mukherjee
  • Patient Rights
  • New technological advances
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Survey
  • Awards & Recognition
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • DONATE
    • Faire un don
    • DONAR
  • About us
    • Our mission
    • Contact us >
      • Nous contacter >
        • Contácte nos.
Chronic Myeloid Leukemia

ASH 2021 - Virtual - CML - Chronic  Myeloid Leukemia



2021 ASH 63th Annual Meeting and Exposition (December 11 - 14, 2021)


Forums and Patient associations  
                      
CML ADVOCATES NETWORK CONFERENCE REPORT  ​by CML Advocates Network     

NEWS

Comparing Asciminib With Bosutinib in Patients With Chronic-Phase Chronic Myeloid Leukemia
December 17, 2021, DocWireNews


ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting
November 4, 2021, PR Newswire



CML Highlights of ASH 2021
            with Professor Susan Branford (Australia)
     and Professor Charles Chuah Thuan Heng (Singapore) 

          iCMLf Conversation: CML Highlights of ASH 2021
         International Chronic Myeloid leukemia Foundation
VIDEOS

ASH 2021: Key Data in Chronic Myeloid Leukemia (Dr. E Jabbour)
February 7, 2022, OncLive


ASH 2021: Good News for CML Treatment (Dr. Michael Mauro)
December 21, 2021, Patient Power


Doctor Shares CML Treatment Updates from ASH 2021 (Dr. Michael Mauro) 
December 21, 2021, Patient Power

ASH 2021: New OPTIC Trial Analysis Shows Ponatinib is Effective in Chronic Myeloid Leukemia Patients
December 14, 2021, CheckRare

Next Steps for Ponatinib
December 14, 2021, CheckRare


Targeting TKI-resistant CML with LY3009120 and asciminib
December 13, 2021, VJHemOnc – Video Journal of Hematological Oncology

 
ASH 2021 highlights in CML
December 12, 2021, VJHemOnc – Video Journal of Hematological Oncology

New Longer-term Efficacy, Safety Data of Asciminib in CML
December 11, 2021, Pharmacy Times

 
CML news to look out for at ASH 2021 (Dr. F.X. Mahon)
December 10, 2021, VJHemOnc – Video Journal of Hematological Oncology


EURO-SKI: 3-year follow-up data of TKI cessation in CML
December 1, 2021, VJHemOnc – Video Journal of Hematological Oncology


ESH CML/MPNs 2021: what to expect?
February 19, 2021, VJHemOnc – Video Journal of Hematological Oncology
​SOME INTERESTING ABSTRACTS FOR CML
​

+++ Treatment-Free Remission

First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib

Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors’ Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience
​
 
+++ Tyrosine Kinase Inhibitors

Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase

The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation

Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations Exploiting LY3009120 and Asciminib Combination to Target TKI-Resistant CML
​
A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
​
Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

The Rate of Cellular Energy Production of Muscle Cells Is Attenuated By Carnitine Intracellular Deficiency Caused By Imatinib Treatment

Evaluating Real-World Effectiveness and Safety of Generic and Brand-Name Imatinib in Chronic Myeloid Leukemia

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response
​
Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Dasatinib Treatment Patterns after Pleural Effusion Among Patients with Chronic Myeloid Leukemia
​
The Comparison of Dasatinib 70 Mg/Day to 100 Mg/Day in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Multicenter, Prospective, Randomized Controlled Study

Efficacy and Safety of Generic Dasatinib As First-Line Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase: Final Analysis with 2-Year Follow-up

Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1 T315I

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials
 
Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

Post Hoc Analysis of Responses to Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) By Baseline BCR-ABL1 Level and Baseline Mutation Status in the Optic Trial

Ponatinib in Combination with FLAG-IDA Chemotherapy for Blast-Phase Chronic Myeloid Leukemia: Final Results of the Seamless Phase I/II Dose-Finding UK Trials Acceleration Programme (TAP) Matchpoint Trial

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)

Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)

An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies

​+++ Pediatric and Elderly Patients

A Multicenter, Prospective Study for Pediatric Chronic Myeloid Leukemia in Chronic Phase: The JPLSG CML-08 Study

Characteristics, Treatment and Outcome of 15 to 18 Years-Old Adolescents with Chronic Myeloid Leukemia (CML): The Experience of the International Registry of Childhood CML (I-CML-Ped Study)

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

​+++

Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence
 
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
​

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A “Campus CML” Study

Between a Rock and a Hard Place: Paraproteinemia Associated with Chronic Myeloid Leukemia

Flow Cytometry Based Identification of CD26+ Leukemic Stem Cells in the Peripheral Blood Has a Potential Role in the Rapid Diagnosis of Chronic Myeloid Leukemia

Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy
​

             
​              Return to other ASH Annual Meetings ​

​
Our disclaimer       Notre avis de non-responsabilité     Nuestro descargo de responsabilidad
  Privacy Policy              Politique de confidentialité                  Politica de Confidencialidad   
                    
Copyright © 2010-2025 CMLeukemia.com
Protected by Copyscape     DMCA.com Protection Status